American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment

David C. Shonka; Alan Ho; Ashish V. Chintakuntlawar; Jessica L. Geiger; Jong C. Park; Nagashree Seetharamu; Sina Jasim; Amr H. Abdelhamid Ahmed; Keith C. Bible; Marcia S. Brose; Maria E. Cabanillas; Kirsten Dabekaussen; Louise Davies; Dora Dias-Santagata; James A. Fagin; William C. Faquin; Ronald A. Ghossein; Raj K. Gopal; Akira Miyauchi; Yuri E. Nikiforov; Matthew D. Ringel; Bruce Robinson; Mabel M. Ryder; Eric J. Sherman; Peter M. Sadow; Jennifer J. Shin; Brendan C. Stack; R. Michael Tuttle; Lori J. Wirth; Mark E. Zafereo; Gregory W. Randolph

doi:10.1002/hed.27025

American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment

David C. Shonka, Alan Ho, Ashish V. Chintakuntlawar, Jessica L. Geiger, Jong C. Park, Nagashree Seetharamu, Sina Jasim, Amr H. Abdelhamid Ahmed, Keith C. Bible, Marcia S. Brose, Maria E. Cabanillas, Kirsten Dabekaussen, Louise Davies, Dora Dias-Santagata, James A. Fagin, William C. Faquin, Ronald A. Ghossein, Raj K. Gopal, Akira Miyauchi, Yuri E. NikiforovMatthew D. Ringel, Bruce Robinson, Mabel M. Ryder, Eric J. Sherman, Peter M. Sadow, Jennifer J. Shin, Brendan C. Stack, R. Michael Tuttle, Lori J. Wirth, Mark E. Zafereo, Gregory W. Randolph

Research output: Contribution to journal › Article › peer-review

Abstract

Background: The development of systemic treatment options leveraging the molecular landscape of advanced thyroid cancer is a burgeoning field. This is a multidisciplinary evidence-based statement on the definition of advanced thyroid cancer and its targeted systemic treatment. Methods: An expert panel was assembled, a literature review was conducted, and best practice statements were developed. The modified Delphi method was applied to assess the degree of consensus for the statements developed by the author panel. Results: A review of the current understanding of thyroid oncogenesis at a molecular level is presented and characteristics of advanced thyroid cancer are defined. Twenty statements in topics including the multidisciplinary management, molecular evaluation, and targeted systemic treatment of advanced thyroid cancer are provided. Conclusions: With the growth in targeted treatment options for thyroid cancer, a consensus definition of advanced disease and statements regarding the utility of molecular testing and available targeted systemic therapy is warranted.

Original language	English (US)
Pages (from-to)	1277-1300
Number of pages	24
Journal	Head and Neck
Volume	44
Issue number	6
DOIs	https://doi.org/10.1002/hed.27025
State	Published - Jun 2022

Keywords

advanced thyroid cancer
consensus statement
molecular testing
systemic therapy
targeted treatment

ASJC Scopus subject areas

Otorhinolaryngology

Access to Document

10.1002/hed.27025

Fingerprint

Dive into the research topics of 'American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment'. Together they form a unique fingerprint.

Cite this

Shonka, D. C., Ho, A., Chintakuntlawar, A. V., Geiger, J. L., Park, J. C., Seetharamu, N., Jasim, S., Abdelhamid Ahmed, A. H., Bible, K. C., Brose, M. S., Cabanillas, M. E., Dabekaussen, K., Davies, L., Dias-Santagata, D., Fagin, J. A., Faquin, W. C., Ghossein, R. A., Gopal, R. K., Miyauchi, A., ... Randolph, G. W. (2022). American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment. Head and Neck, 44(6), 1277-1300. https://doi.org/10.1002/hed.27025

American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment. / Shonka, David C.; Ho, Alan; Chintakuntlawar, Ashish V. et al.
In: Head and Neck, Vol. 44, No. 6, 06.2022, p. 1277-1300.

Research output: Contribution to journal › Article › peer-review

Shonka, DC, Ho, A, Chintakuntlawar, AV, Geiger, JL, Park, JC, Seetharamu, N, Jasim, S, Abdelhamid Ahmed, AH, Bible, KC, Brose, MS, Cabanillas, ME, Dabekaussen, K, Davies, L, Dias-Santagata, D, Fagin, JA, Faquin, WC, Ghossein, RA, Gopal, RK, Miyauchi, A, Nikiforov, YE, Ringel, MD, Robinson, B, Ryder, MM, Sherman, EJ, Sadow, PM, Shin, JJ, Stack, BC, Tuttle, RM, Wirth, LJ, Zafereo, ME & Randolph, GW 2022, 'American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment', Head and Neck, vol. 44, no. 6, pp. 1277-1300. https://doi.org/10.1002/hed.27025

@article{3f57096d725e488a9058dbab16416f05,

title = "American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment",

abstract = "Background: The development of systemic treatment options leveraging the molecular landscape of advanced thyroid cancer is a burgeoning field. This is a multidisciplinary evidence-based statement on the definition of advanced thyroid cancer and its targeted systemic treatment. Methods: An expert panel was assembled, a literature review was conducted, and best practice statements were developed. The modified Delphi method was applied to assess the degree of consensus for the statements developed by the author panel. Results: A review of the current understanding of thyroid oncogenesis at a molecular level is presented and characteristics of advanced thyroid cancer are defined. Twenty statements in topics including the multidisciplinary management, molecular evaluation, and targeted systemic treatment of advanced thyroid cancer are provided. Conclusions: With the growth in targeted treatment options for thyroid cancer, a consensus definition of advanced disease and statements regarding the utility of molecular testing and available targeted systemic therapy is warranted.",

keywords = "advanced thyroid cancer, consensus statement, molecular testing, systemic therapy, targeted treatment",

author = "Shonka, {David C.} and Alan Ho and Chintakuntlawar, {Ashish V.} and Geiger, {Jessica L.} and Park, {Jong C.} and Nagashree Seetharamu and Sina Jasim and {Abdelhamid Ahmed}, {Amr H.} and Bible, {Keith C.} and Brose, {Marcia S.} and Cabanillas, {Maria E.} and Kirsten Dabekaussen and Louise Davies and Dora Dias-Santagata and Fagin, {James A.} and Faquin, {William C.} and Ghossein, {Ronald A.} and Gopal, {Raj K.} and Akira Miyauchi and Nikiforov, {Yuri E.} and Ringel, {Matthew D.} and Bruce Robinson and Ryder, {Mabel M.} and Sherman, {Eric J.} and Sadow, {Peter M.} and Shin, {Jennifer J.} and Stack, {Brendan C.} and Tuttle, {R. Michael} and Wirth, {Lori J.} and Zafereo, {Mark E.} and Randolph, {Gregory W.}",

note = "Publisher Copyright: {\textcopyright} 2022 Wiley Periodicals LLC.",

year = "2022",

month = jun,

doi = "10.1002/hed.27025",

language = "English (US)",

volume = "44",

pages = "1277--1300",

journal = "Head and Neck",

issn = "1043-3074",

publisher = "Wiley-Liss Inc.",

number = "6",

}

TY - JOUR

T1 - American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer

T2 - Defining advanced thyroid cancer and its targeted treatment

AU - Shonka, David C.

AU - Ho, Alan

AU - Chintakuntlawar, Ashish V.

AU - Geiger, Jessica L.

AU - Park, Jong C.

AU - Seetharamu, Nagashree

AU - Jasim, Sina

AU - Abdelhamid Ahmed, Amr H.

AU - Bible, Keith C.

AU - Brose, Marcia S.

AU - Cabanillas, Maria E.

AU - Dabekaussen, Kirsten

AU - Davies, Louise

AU - Dias-Santagata, Dora

AU - Fagin, James A.

AU - Faquin, William C.

AU - Ghossein, Ronald A.

AU - Gopal, Raj K.

AU - Miyauchi, Akira

AU - Nikiforov, Yuri E.

AU - Ringel, Matthew D.

AU - Robinson, Bruce

AU - Ryder, Mabel M.

AU - Sherman, Eric J.

AU - Sadow, Peter M.

AU - Shin, Jennifer J.

AU - Stack, Brendan C.

AU - Tuttle, R. Michael

AU - Wirth, Lori J.

AU - Zafereo, Mark E.

AU - Randolph, Gregory W.

PY - 2022/6

Y1 - 2022/6

N2 - Background: The development of systemic treatment options leveraging the molecular landscape of advanced thyroid cancer is a burgeoning field. This is a multidisciplinary evidence-based statement on the definition of advanced thyroid cancer and its targeted systemic treatment. Methods: An expert panel was assembled, a literature review was conducted, and best practice statements were developed. The modified Delphi method was applied to assess the degree of consensus for the statements developed by the author panel. Results: A review of the current understanding of thyroid oncogenesis at a molecular level is presented and characteristics of advanced thyroid cancer are defined. Twenty statements in topics including the multidisciplinary management, molecular evaluation, and targeted systemic treatment of advanced thyroid cancer are provided. Conclusions: With the growth in targeted treatment options for thyroid cancer, a consensus definition of advanced disease and statements regarding the utility of molecular testing and available targeted systemic therapy is warranted.

AB - Background: The development of systemic treatment options leveraging the molecular landscape of advanced thyroid cancer is a burgeoning field. This is a multidisciplinary evidence-based statement on the definition of advanced thyroid cancer and its targeted systemic treatment. Methods: An expert panel was assembled, a literature review was conducted, and best practice statements were developed. The modified Delphi method was applied to assess the degree of consensus for the statements developed by the author panel. Results: A review of the current understanding of thyroid oncogenesis at a molecular level is presented and characteristics of advanced thyroid cancer are defined. Twenty statements in topics including the multidisciplinary management, molecular evaluation, and targeted systemic treatment of advanced thyroid cancer are provided. Conclusions: With the growth in targeted treatment options for thyroid cancer, a consensus definition of advanced disease and statements regarding the utility of molecular testing and available targeted systemic therapy is warranted.

KW - advanced thyroid cancer

KW - consensus statement

KW - molecular testing

KW - systemic therapy

KW - targeted treatment

UR - http://www.scopus.com/inward/record.url?scp=85126054106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85126054106&partnerID=8YFLogxK

U2 - 10.1002/hed.27025

DO - 10.1002/hed.27025

M3 - Article

C2 - 35274388

AN - SCOPUS:85126054106

SN - 1043-3074

VL - 44

SP - 1277

EP - 1300

JO - Head and Neck

JF - Head and Neck

IS - 6

ER -

American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this